NKTX
NKTX clinical trials: Nkarta, Inc.
Every trial on ClinicalTrials.gov where Nkarta, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5
- Trials linked
- 4
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
NKTX on the catalyst calendar · NKTX registry changes
- Primary completion Oct 2028Sponsor estimatePhase 1/Phase 2NCT06733935A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)Nkarta, Inc. · Systemic SclerosisRecruitingNKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 1/Phase 2NCT06557265A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)Nkarta, Inc. · Lupus NephritisRecruitingNKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2025ActualPhase 1NCT05020678NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersNkarta, Inc. · Lymphoma, Non-HodgkinActive, not recruitingNKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2, 2024ActualPhase 1NCT04623944NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDSNkarta, Inc. · Relapsed/Refractory AMLActive, not recruitingNKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT06518668A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus ErythematosusHospital for Special Surgery, New York · Systemic Lupus ErythematosusEnrolling by invitationNKTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner